Details of the Drug
General Information of Drug (ID: DMU9F7K)
Drug Name |
S-2-(o-toluidino)-2-oxoethyl carbamothioate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5429-04-9; carbamoylsulfanyl-acetic acid o-toluidide; NSC13347; AC1L5DGT; AC1Q5NMD; Oprea1_302154; MLS000085728; CHEMBL236685; ZINC69645; MolPort-002-702-780; HMS2293B23; STK795741; carbamothioic acid, s-[2-[(2-methylphenyl)amino]-2-oxoethyl] ester; NSC-13347; AKOS001735942; MCULE-9952660100; SMR000020857; EU-0051903; SR-01000520769; SR-01000520769-1; S-[2-(2-methylanilino)-2-oxoethyl] carbamothioate; S-{2-[(2-methylphenyl)amino]-2-oxoethyl} thiocarbamate; S-{2-[(2-methylphenyl)amino]-2-oxoethyl} carbamothioate; A1844/0077558
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 224.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||